- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02593929
Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer
June 6, 2017 updated by: University of Pittsburgh
Pharmacodynamic Effects and Predictive Biomarkers of JAK/STAT Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial
This study will identify baseline and/or pharmacodynamic biomarkers of response to ruxolitinib, based upon association with quantitative change in tumor size following 14-21 days of neoadjuvant ruxolitinib in patients with operable HNSCC.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
In this study, ruxolitinib will be administered for a short period of 2-3 weeks prior to planned surgical resection of HNSCC.
The dose will be 20 mg twice daily, the FDA-approved dose in myelofibrosis.
The brief treatment duration is within the expected window of time that elapses from initial patient evaluation by a surgeon to performance of surgery.
In the phase 0 or window trial model, a paired specimen analysis permits ex vivo evaluation of target modulation and pharmacodynamic changes in downstream or parallel molecular pathways.32
This study design is optimal in order to assess the biochemical and immunomodulatory effects of ruxolitinib on HNSCC.
Furthermore, predictive biomarkers can be developed as related to a clinical endpoint or a biochemical, pharmacodynamic endpoint.
Study Type
Interventional
Phase
- Early Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically or cytologically confirmed, primary or recurrent, head and neck squamous cell carcinoma, including variants. Patients must have at least one measureable lesion in accordance with RECIST 1.1 (tumor diameter ≥ 1 cm; short-axis lymph node diameter ≥ 1.5 cm) OR by caliper measurement (tumor diameter ≥ 1 cm). Any diagnostic pretreatment biopsy sample is acceptable including FNA.
- Primary tumors of any head and neck (oral cavity, oropharynx, hypopharynx, or larynx) site will be included.
- Surgical resection of head and neck must be planned, either as primary treatment or salvage. Patients must undergo research biopsy prior to receiving drug.
- Age ≥ 18 years.
- ECOG performance status 0-2 (See Appendix I).
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test (sensitivity ≤ 25IU HCG/L) within 4 weeks prior to registration and will be repeated within 72 hours prior to the start of study drug administration.
- Persons of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 12 weeks after study drug is stopped. Prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.
Adequate hematologic, renal and hepatic function, as defined by:
- Absolute neutrophil count (ANC) ≥ 1,500/ul, platelets ≥ 150,000/ul.
- Creatinine ≤ 1.5 x institutional upper limit of normal (ULN).
- Bilirubin ≤ 1.5 x ULN, AST or ALT ≤ 2.5 x ULN.
- Have signed written informed consent
Exclusion Criteria:
- Subjects who fail to meet the above criteria.
- Prior therapy for head and neck cancer is allowed, and the number of treatments is not limited. However, any systemic therapy should have been completed at least 30 days prior to study enrollment. Any radiation to the head and neck should have been completed at least 30 days prior to study enrollment. Palliative radiation outside of the head and neck does not require a washout.
- Pregnancy or breastfeeding. Women (patients or partners of male patients) of childbearing potential (WOCBP) must practice acceptable methods of birth control to prevent pregnancy. All WOCBP MUST have a negative pregnancy test within 4 weeks prior to registration, and this must be repeated within 72 hours prior to first receiving ruxolitinib. If the pregnancy test is positive, the patient must not receive ruxolitinib and must not be enrolled in the study.
- Any unresolved chronic toxicity ≥ grade 2 from previous anticancer therapy (except alopecia and anemia), according to Common Terminology Criteria for Adverse Events v4.0 (CTCAE).
- Current active infection requiring systemic antibiotic or antifungal therapy.
- Acute hepatitis or known HIV.
- Treatment with a non-approved or investigational drug within 30 days prior to Day 1 of study treatment.
- New York Heart Association (NYHA) Class III or IV heart disease.
- History of thromboembolic event or other condition currently requiring anticoagulation with warfarin (coumadin). Patients who are treated with low molecular weight heparin or fondaparinux are eligible.
- History of significant bleeding disorder unrelated to cancer, including: diagnosed congenital bleeding disorders (e.g., von Willebrand's disease, diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies, or ongoing or recent (≤ 3 months) significant gastrointestinal bleeding
- Concomitant Medications, any of the following should be considered for exclusion: Strong CYP3A4 inhibitors: (Patients must discontinue drug 7 days prior to starting ruxolitinib), including but not limited to boceprevir, clarithromycin, conivaptam, indinavir, itraconazle, ketoconazole, lopinavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, or voriconazole. In addition, patients will be instructed to avoid grapefruit or grapefruit juice, starfruit, or seville oranges.
- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ruxolitinib
Ruxolitinib will be taken orally for 14-21 days prior to surgery, every morning and every evening, and will be discontinued after the morning dose on the day of planned surgical resection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
baseline and/or pharmacodynamic biomarkers of response to ruxolitinib based upon association with change in tumor size
Time Frame: 14-21 days
|
14-21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
preliminary efficacy of neoadjuvant ruxolitinib in patients with operable HNSCC as determined by quantitative ΔTumor size
Time Frame: 14-21 days
|
14-21 days
|
|
the tolerability of brief neoadjuvant exposure to ruxolitinib as determined by the number of participants with treatment related adverse events as assessed by CTCAE v4.0
Time Frame: 14-21 days
|
14-21 days
|
|
the effect of ruxolitinib on the tumoral Ki-67 proliferation index
Time Frame: 14-21 days
|
Evaluate the change in the KI-67 proliferation index after exposure to ruxolitinib.
Ki-67 immunohistochemistry will be performed with the Dako North America M7240 antibody and scored quantitatively with Aperio computer-assisted digital analysis by the research pathologist.
In keeping with international consensus guidelines, at least 5000 tumor cells/specimen will be counted.
The percentage of positive tumor cells represents the proliferation index.
|
14-21 days
|
additional candidate biomarkers of ruxolitinib response or resistance in HNSCC patients as determined by quantitative ΔTumor size
Time Frame: 14-21 days
|
14-21 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2017
Primary Completion (Anticipated)
January 1, 2018
Study Registration Dates
First Submitted
October 14, 2015
First Submitted That Met QC Criteria
October 30, 2015
First Posted (Estimate)
November 1, 2015
Study Record Updates
Last Update Posted (Actual)
June 8, 2017
Last Update Submitted That Met QC Criteria
June 6, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UPCI 14-207
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Squamous Cell Carcinoma
-
Washington University School of MedicineMerck Sharp & Dohme LLCActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Chase Heaton, MDIncyte Corporation; OncoSec Medical IncorporatedTerminatedRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell CarcinomaUnited States
-
Xiang LuRecruitingHead and Neck Squamous Cell Carcinomas | Resectable Head and Neck Squamous-cell CarcinomaChina
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...United States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingHead and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell CarcinomaUnited States
-
Washington University School of MedicineActive, not recruitingSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Medical College of WisconsinRecruitingResectable Head and Neck Squamous Cell CarcinomaUnited States
-
Yonsei UniversityCompletedHead Neck Cancer Squamous Cell Recurrent | Head Neck Cancer Squamous Cell MetastaticKorea, Republic of
-
Bristol-Myers SquibbActive, not recruitingSquamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and NeckFrance
-
National Taiwan University HospitalUnknownHead-and-Neck Squamous Cell CarcinomaTaiwan
Clinical Trials on ruxolitinib
-
First Affiliated Hospital of Zhejiang UniversityXiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaboratorsRecruitingHematologic Malignancy | Bronchiolitis Obliterans SyndromeChina
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
-
Incyte CorporationActive, not recruiting
-
Julie NangiaIncyte Corporation; Translational Breast Cancer Research ConsortiumRecruitingDuctal Carcinoma In Situ | Atypical Ductal Hyperplasia | Atypical Lobular Hyperplasia | Lobular Carcinoma In SituUnited States
-
University of ZurichIncyte CorporationNot yet recruitingExanthema | Lichenoid Skin Rashes Under Anti-PD1 Tumor Therapy
-
Beijing Friendship HospitalUnknownHemophagocytic LymphohistiocytosisChina
-
Children's Hospital Medical Center, CincinnatiRecruitingBronchiolitis Obliterans (BO) | Hematopoietic Stem Cell Transplant (HSCT)United States
-
University of JenaCompleted
-
University of Michigan Rogel Cancer CenterCompletedHemophagocytic Syndrome (HPS)United States
-
Margherita MaffioliUnknown